301 related articles for article (PubMed ID: 31465912)
1. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
Xu S; Zhang X; Pan M; Shuai Z; Xu S; Pan F
Int Immunopharmacol; 2019 Oct; 75():105841. PubMed ID: 31465912
[TBL] [Abstract][Full Text] [Related]
2. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ; Warren RB; Cather JC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
[TBL] [Abstract][Full Text] [Related]
3. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
Xu S; Gao X; Deng J; Yang J; Pan F
J Dtsch Dermatol Ges; 2021 Jan; 19(1):47-56. PubMed ID: 33377312
[TBL] [Abstract][Full Text] [Related]
7. Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
Yang J; Wang Z; Zhang X
J Immunol Res; 2020; 2020():4975628. PubMed ID: 32724829
[TBL] [Abstract][Full Text] [Related]
8. Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis.
Hou M; Xing H; Cai Y; Wang X; Xie Z; Zhang Q; Ma Y; Chen J
Eur J Dermatol; 2019 Jun; 29(3):302-314. PubMed ID: 31389789
[TBL] [Abstract][Full Text] [Related]
9. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
11. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
12. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
[TBL] [Abstract][Full Text] [Related]
13. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
15. Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
Paton DM
Drugs Today (Barc); 2019 Oct; 55(10):605-613. PubMed ID: 31720558
[TBL] [Abstract][Full Text] [Related]
16. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
McDonald J; Maliyar K; Gooderham MJ
Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
[TBL] [Abstract][Full Text] [Related]
17. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
20. Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L; Maloney V; Gordon KB
Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
